Canada: FCA Sends Differin Pricing Matter Back To PMPRB

The Canadian Federal Court of Appeal (FCA) has released an important decision in Canada (Attorney General) v. Galderma Canada Inc. (Galderma), affirming the lower court's approach in assessing whether the Patented Medicine Prices Review Board (PMPRB) has jurisdiction over a drug product sold in Canada.

What is Canada's PMPRB?

The PMPRB is an administrative board established by the Patent Act with a mandate to protect Canadians from excessive drug pricing. The PMPRB controls the introductory price at which a medicine (drug product) is launched and limits the annual price increases manufacturers of patented drugs can apply. Patentees are required to report applicable patents, and file sales information so the PMPRB can monitor for excessive pricing as long as the product is considered to be a patented medicine. If it is determined the average price for a patented medicine is too high, a patentee must make a payment to PMPRB to set off the excessive revenues that were generated.

In order for the PMPRB to have jurisdiction over a medicine sold in Canada, there must be a patent that "pertains" to the medicine. Under the Patent Act, an invention pertains to a medicine if the invention is intended or capable of being used for medicine or for the preparation or production of medicine. Case law has established that the term "pertains" must be interpreted broadly in order for the consumer protection mandate of the PMPRB to be respected. PMPRB is not required to perform a claim construction analysis as would be done in a patent infringement proceeding. Instead, a patent will pertain to a medicine when there is a "mere slender thread" of nexus between the invention described in a patent and the medicine sold in Canada.

Facts of Galderma

The facts of Galderma relate to two medicines: Differin (a formulation of adapalene in a concentration of 0.1%) and Differin XP (a sustained release 0.3% formulation). Patents coving Differin had been reported to PMPRB by the manufacturer, Galderma Canada Inc., up until their expiry in 2009. A different patent had been reported in respect of Differin XP, which expired in 2016. PMPRB staff believed the later patent to the 0.3% formulation should have been reported in the post-2009 period for Differin, even though Differin is a 0.1% formulation of adapalene. After a hearing was conducted, PMPRB concluded the later patent pertained to the medicine Differin and ought to have been reported, such that Differin would have been under price control until 2016.

Lower Court Ruling

Galderma sought judicial review of the PMPRB's ruling before the Federal Court, where the Court held that PMPRB made two critical errors in its decision.

First, the Federal Court ruled that the focus of the analysis on whether a patent "pertains" should be a determination of whether the invention in the patent pertains to the medicine. The court observed that since the PMPRB had used the terms "patent" and "invention" interchangeably in its decision, it was not clear to the Court that the PMPRB was aware these terms had distinct meanings under the Patent Act. The Court ruled the PMPRB did not identify the invention in the later patent and failed to consider whether the 0.3% extended release formulation disclosed in the later patent was intended or capable of being used for the original 0.1% Differin medicine. Thus, PMPRB wrongly focused on considerations other than the actual invention disclosed in the patent.

Second, while the Court agreed with the PMPRB that the proper analysis is to review the "face of the patent" when deciding whether an invention pertains to a medicine, this review requires that patent be reviewed as a whole. This would include the claims, description, and described scope of the invention. The Court found the PMPRB failed to review the later patent "holistically" and therefore erred in concluding the later patent covered more than a 0.3% extended release formulation. Thus, it was unreasonable for PMPRB to conclude that on its face the later patent pertained to Differin.

Federal Court of Appeal decision

The Federal Court decision was appealed to the FCA, which affirmed the lower court's approach to patent review, and agreed the PMPRB had erred in its assessment of the patented invention.

The FCA held it was unreasonable for PMPRB to limit its analysis to only selected portions of the patent. The FCA noted that to discharge PMPRB's mandate of regulating the prices of patented medicines, it must have a sufficient understanding of the invention of a patent. While this does not require the review to go beyond the "face of the patent", PMPRB must read the patent as a whole, not just certain introductory phrases. The FCA found that PMPRB unreasonably limited its review to the abstract and an introductory paragraph in reaching its conclusion and failed to consider the critical parts of the patent—in particular, the claims.

Second, the FCA agreed with the lower court in that PMPRB did not determine the invention of the patent. Instead, it limited its reading to a cursory examination of whether the patent related exclusively to a 0.3% adapalene formulation. Upon reviewing various parts of the description, including the background of invention, the objective of the patent, various formulations and examples, and benefits of the invention, as well as the claims, the FCA concluded that the invention of the patent is a 0.3% adapalene formulation used in treating dermatological conditions such as common acne. As such, PMPRB's finding that the patent does not relate exclusively to a 0.3% adapalene formulation is erroneous and unreasonable.

In determining whether the patent pertains to the medicine, the FCA provided further clarification on what the "medicine" is and what "pertain" entails. On appeal, the Attorney General argued that the medicine in issue is adapalene, not Differin, and further argued this was the position taken by PMPRB. The FCA disagreed with this position and observed that PMPRB in its decision repeatedly referred to Differin, the commercial preparation, as the medicine to which the patent pertains, not adapalene, the active ingredient. The FCA reasoned that, in view of PMPRB's mandate and to give rise to the question of excessive pricing, the medicine would have to be the commercial preparation that was sold in Canada at the relevant time. As such, it was reasonable for PMPRB to conclude in its decision that the medicine is Differin.

The FCA clarified the test to determine whether an invention pertains to a medicine is set out at subsection 79(2) of the Patent Act. The question to ask is whether the "invention is intended or capable of being used for medicine or for the preparation or production of medicine", not whether there is the "merest slender thread" of a connection. The FCA further clarified that the expression "merest slender of thread" was used in jurisprudence as a metaphor for the idea that the connection between an invention and a medicine may be tenuous, not a test designed to replace or substitute the statutory definition of "pertain".

Back to the board

Taken together, the FCA reasoned that if PMPRB's decision rested solely on its erroneous and unreasonable conclusion that the patent does not relate exclusively to a 0.3% adapalene formulation, then its decision should be quashed. However, it was unclear to the FCA whether PMPRB's decision may have been influenced by other factors that were referred to in PMPRB's decision. The FCA observed that there had been evidence before PMPRB regarding clinical similarities between Differin and Differin XP. The question of what kind of clinical similarities would support a finding that the invention of a patent pertains to, or was intended or capable of being used for that medicine, was not addressed by the FCA and remains to be answered.

As such, the matter is not yet concluded and has been returned to PMPRB for redetermination based on a proper understanding of the patented invention provided by the FCA. The FCA returned the matter to PMPRB and invited it to consider what clinical similarities between Differin and Differin XP would support a finding that a patented invention was intended or capable of being used for that medicine. It commented that PMPRB must complete its inquiry on the basis of a proper understanding of the invention of the patent (i.e., the one the FCA provided in its decision). Namely, that the invention is the use of 0.3% concentration of adapalene for the treatment of dermatological disorders. The FCA also determined that the medicine is the commercial formulation, rather than the active ingredient.

Implications

This decision elevates the threshold required to be met by PMPRB in establishing a connection between a patented invention and a commercialized medicine.

The FCA decision affirms the approach to patent review and provides further clarification to jurisprudence in determining whether the invention of a patent pertains to a medicine. The decision shows that while the connection between an invention and a medicine may be tenuous, the "merest slender thread" is not a test designed to supplant the statutory test of "pertain".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions